Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - ...
Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - ...
>On most key headlines, Basic-Fit reported in-line Q1 2024 results - Basic-Fit reported 4.05m memberships, 1,506 clubs and revenue of € 284m in Q1 2024. We had forecasts 4.055m memberships, 1,510 clubs and € 290m in revenue (there is no reliable consensus available). The average monthly revenue per membership amounted to € 23.57, which was a tad lower than our forecast of € 23.67. The number of clubs were as expected in France (814) and in Spain (199), a tad below our...
Basic-Fit: 1Q24 update in line, FY24 outlook in line with consensus at mid-point. bpost: Agreement on Flemish newspaper delivery; risk of provisions largely removed. Cofinimmo: Q1 results in line. Corbion: Tail wags the dog. IMCD: The last hurdle was a harsh clip. Proximus: Strong start to the year, guidance unchanged ahead of Digi arrival. Recticel: Kingspan 1Q24 trading update. Signify: 1Q24 results; revenue decline accelerates. Umicore: Confirms FY 2024 EBITDA guidance range. ...
A director at D`ieteren Group sold 5,000 shares at 205.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Mithra secures court protection measures to advance monetization process Court Grants "Transfer under Judicial Supervision" for CDMO facility, safeguarding Mithra's activities and expediting the M&A process for its Contract Development and Manufacturing Organization.Approval of Judicial Reorganization Proceedings for Novalon SA, facilitating an amicable agreement with some creditors and restructuring the debt of Mithra's complex therapeutics business.Mithra Advances Monetization Process with Court Protection Measures, marking significant milestones in the company's commitment to maximizing ...
>Growth in clubs, members and revenue seen skewed to H1 2024 - Basic-Fit is set to report its Q1 2024 trading update on 26 April at 07:30. In its Q1 and Q3 updates, Basic-Fit only reports on the number of clubs, memberships, revenue and yield only. Furthermore, Basic-Fit does not host a conference call following its Q1 and Q3 updates. Including the 47 Spanish clubs acquired from RSG Group on 27 March, we forecast 1,510 clubs (+19.1%), or well on track to achieve 1,575...
argenx announced additional detail on its Phase 3 ADHERE data with Vyvgart Hytrulo, showcasing its speed of onset and depth of response. We believe that Vyvgart Hytrulo is well positioned vs. the approved standard-of-care IVIg/SCIg across patient types, and look forward to the FDA decision (PDUFA: June 21, 2024). € 435 TP and Buy rating reiterated.
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART® treatment April 16, 2024 – 7:00am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, ...
• ARGX shared additional results from the ADHERE (open-label) study and real-world data from gMG patients at the AAN Annual Meeting. • Data indicates rapid, deep, and clinically meaningful/sustained improvements in CIDP & with ability to reduce steroid burden (gMG). • We expect a positive outcome of the decision on regulatory approval for CDP by June 21 (85% LoA, +4% impact on TP) and currently project low double-digit million in sales this year. This might seem rather conservative (vs. gMG init...
On May 3, we expect Ontex to publish its 7th consecutive quarter of EBITDA growth. More importantly, we expect this strong trend to continue. The increase in EBITDA and lower financial charges should result in strong earnings growth.Deleverage is expected to continue and will get another boost from the expected sale of its Brazilian and Turkish activities. The improved financial position should also allow for a smooth refinancing exercise. Given this all, we expect a further rise in the share pr...
Ontex announces details for its Q1 2024 results publication Aalst, Belgium, April 12, 2024 – Ontex Group NV, a leading international provider of personal care solutions, will share its results for the first quarter of 2024 at 07:00 CEST / 06:00 BST on Friday, May 3, 2024. Management will host a webcast for investors and analysts on the same day at 12:00 CEST / 11:00 BST. Click on the following link to attend the presentation from your laptop, tablet or mobile device: . A replay of the webcast will be available at the same link shortly after the conclusion of the live presentation, and re...
Ontex kondigt details aan voor de resultatenpublicatie van het 1ste kwartaal van 2024 Aalst, België, 12 april 2024 – Ontex Group NV, een toonaangevende internationale leverancier van oplossingen in persoonlijke hygiëne, zal zijn resultaten van het eerste kwartaal van 2024 delen om 07:00 uur CEST / 06:00 uur BST op vrijdag 3 mei 2024. Het directiecomité zal op dezelfde dag een webcast voor investeerders en analisten opzetten om 12:00 uur CEST / 11:00 uur BST. Klik op volgende link om de presentatie bij te wonen vanop uw laptop, tablet of mobiel apparaat: . Deze webcast zal in het Engels plaa...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.